Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study

Click to increase image sizeClick to decrease image size

Disclosure statement

Oliver G. Ottmann received honoraria for advisory board participation from Novartis, Sun Pharma, Fusion Pharma, Roche, and Incyte; Frank Stegelmann and Massimo Breccia received personal fees from Novartis, BMS, Pfizer, and Incyte; Juan Luis Steegmann received grants, personal fees, and non-financial support from BMS and Novartis, and grants and personal fees from Incyte/ARIAD and Pfizer; Eduardo Olavarria had nothing to disclose; Jeffrey H. Lipton received grants from BMS, Novartis, Pfizer, and Takeda; Paola Aimone is employee of Novartis.

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

Additional information

Funding

The study was sponsored by Novartis Pharmaceuticals, AG, Basel.